OSE Immunotherapeutics

USPTO Trademark & Patent Filings

Trademark applications and grants for Ose Immunotherapeutics. Ose Immunotherapeutics has 16 trademark applications. The latest application filed is for "OSE IMMUNOTHERAPEUTICS"

Company Profile

OSE Immunotherapeutics
immunotherapeutics ose
OSE IMMUNOTHERAPEUTICS - Nantes FR
OSE Immunotherapeutics - Nantes FR
OSE IMMUNOTHERAPEUTICS - NANTES FR

State Incorporated	FRANCE
Entity Type	sociÃ©tÃ© anonyme (sa)
Address	22 Boulevard Benoni Goullin Nantes FRANCE 44200

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Trademarks Patents

Patent Applications

Patent Application	Date
METHODS AND COMPOSITIONS FOR MODIFYING MACROPHAGE POLARIZATION INTO PRO-INFLAMMATORY CELLS TO TREAT CANCER 20220298259 - 17/747798 Poirier; Nicolas ; et al.	2022-09-22
Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious Diseases 20220281993 - 17/749856 Poirier; Nicolas ; et al.	2022-09-08
ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS 20220281991 - 17/681219 POIRIER; Nicolas ; et al.	2022-09-08
METHODS FOR PROMOTING T CELLS RESPONSE 20220281983 - 17/740849 CHIFFOLEAU; Elise ; et al.	2022-09-08
METHOD FOR MANUFACTURING A STABLE EMULSION FOR PEPTIDE DELIVERY 20220259277 - 17/736113 CONDUZORGUES; JEAN-PASCAL	2022-08-18
Method for treating a pathological condition involving the activation or proliferation of CD127 positive cells with an anti-CD127 antibody 11,440,964 - 16/532,000 Poirier , et al. September 13, 2	2022-09-13
Method for treating a pathological condition involving the activation or proliferation of CD127 positive cells with an anti-CD127 antibody 11,440,964 - 16/532,000 Poirier , et al. September 13, 2	2022-09-13
Methods for promoting t cells response by administering an antagonist of human c-type lectin-like receptor 1 (CLEC-1) 11,365,257 - 16/343,757 Chiffoleau , et al. June 21, 2	2022-06-21
Methods for promoting t cells response by administering an antagonist of human c-type lectin-like receptor 1 (CLEC-1) 11,365,257 - 16/343,757 Chiffoleau , et al. June 21, 2	2022-06-21
Humanized anti-human-PD-1 antibody and its use in cancer treatment 11,352,430 - 17/414,967 Poirier , et al. June 7, 2	2022-06-07

Patent Grants & Applications

Trademark Applications

Mark Image Registration \| Serial	Trademark Application Date
"OSE IMMUNOTHERAPEUTICS" 98617134	OSE IMMUNOTHERAPEUTICS 2024-06-25
"OSE-CYTOMASK" 98098883	OSE-CYTOMASK 2023-07-24
"OSE-CYTOMASK" 98098906	OSE-CYTOMASK 2023-07-24
"OSE-CYTOMASK" 98098791	OSE-CYTOMASK 2023-07-24
"ARTEMIA" 97810640	ARTEMIA 2023-02-24
"MEMOPI" 97263022	MEMOPI 2022-02-11
"TEDOPI" 97092394	TEDOPI 2021-10-26
"B-COOL" 88136288	B-COOL 2018-09-28
"B-TIC" 6082824 88103604	B-TIC 2018-09-04
"BICKI" 5855074 88103626	BICKI 2018-09-04
"BICKAN" 6082825 88103678	BICKAN 2018-09-04
"ATALANTE" 5231070 87092387	ATALANTE 2016-07-04
"OSE IMMUNOTHERAPEUTICS" 5320086 86942598	OSE IMMUNOTHERAPEUTICS 2016-03-16
"TEDOPI" 4840524 86555498	TEDOPI 2015-03-06
"MEMOPI" 4816485 86442677	MEMOPI 2014-11-03
"OSE PHARMA" 4776010 86442693	OSE PHARMA 2014-11-03

Company Registrations

NCAGE Code	FBFH9	OSE IMMUNOTHERAPEUTICS
CAGE Code	FBFH9	OSE IMMUNOTHERAPEUTICS OSE IMMUNOTHERAPEUTICS
S.A.M. Registration	FBFH9 [276039133]	OSE IMMUNOTHERAPEUTICS

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.